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Purpose/Objective: Radical brachytherapy results in good function 
and organ preservation for lip cancers. However there are changes in 
geometry due to tumor shrinkage and reduction in the post treatment 
oedema which can have impact on the dose distribution. The aim of 
this paper was investigate the need for adaptive brachytherapy using 
2 plans done before and after 5th fractions.  
Materials and Methods: Twelve consecutive lip cancer patients with 
T1 and T2 tumors who underwent radical bachytherapy during July 
2009 to July 2011 were considered for this prospective study. 
Interstitial brachytherapy was done using flexible nylon catheter 
technique under general anesthesia. After the procedure, for each 
patient postimplant planning computerized tomography (CT) scans 
were taken with 2 mm slice thickness and images were transferred to 
PLATO Sunrise treatment planning system. Dosimetry was 
geometrically optimized on volume and the dose was prescribed to 
the isodose covering the implant volume as evaluated on the axial 
slices. The dose-volume histograms were generated for each plan and 
the coverage volumes of 100%, 150% and 200% were obtained. Dose 
Nonuniformity Ratio (DNR), Dose Homogeneity Index (DHI) and 
Overdose volume index (ODI) were also documented. The dose of 35-
49 Gy was given in 10-14 fractions (350cGy/fraction), twice daily. 
Treatment planning CT scan was repeated before 6th fractions and re-
planning was done taking into considerations change of soft tissue 
edema. 
Results: Mean D100 was 5.76 CC (SD 1.37) and 5.17 CC (SD 1.35) at 
1stfraction and before 6th fraction respectively. Mean D150 were 
1.62CC (SD 0.37) and 1.47 CC (SD 0.42) respectively Mean D200 was 
0.773 CC (SD0.16) and 0.66 CC (SD 0.17) respectively. Mean DNR was 
0.2836 (SD 0.0343) and0.2856 (SD 0.0342) for 1st to 5th fraction and 
from 5thto last fraction respectively. Mean DHI was 0 .7164 (SD 0.0343) 
and 0.7144 (SD0.0342) before and after 5th fraction respectively. Mean 
ODI was0.1361 (SD 0.0163) and 0.1288 (SD 0.118) before and after 
5thfraction. Change in the active loading lengths and change in the 
prescription isodoses of the 2 plans were also documented.  
Conclusions: Tumor shrinkage and reduction in oedma resulted in 
change in the loading lengths. There was reduction in the high dose 
volume of 150 and 200% isodose resulting reduction of ODI. Change in 
the prescription isodose was required in 2 patients. Adaptive 
brachytherapy results in decrease in the high dose region and 
improved coverage and hence should ideally be considered for all 
patients who are treated with nylon tube technique for radical 
brachytherapy of lip cancer. 
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Purpose/Objective: To evaluate the outcomes of two perspective 
studies about patients affected by unresectable extrahepatic 
cholangiocarcinoma treated with radiotherapy (ERT) and concurrent 
chemotherapy (CT) with or without intraluminal brachytherapy (BT). 
Materials and Methods: We analyzed patients with unresectable non 
metastatic extrahepatic bile tumors treated in our Institution in two 
different periods: between 1991 and 1997, the patients received 
external beam radiation therapy and concomitant chemotherapy with 
5-fluorouracil (Group 1). Among them, some patients received a boost 
of intraluminal (low dose rate) brachytherapy with 192Ir, 1 cm from the 
source axis. Instead, between June 1998 to December 2010, the 
patients underwent chemotherapy with Gemcitabine concurrently 
with the same radiotherapy schedule (Group 2) and boost of high dose 
rate brachytherapy. The outcomes of patients was evaluated in terms 
of response to therapy, local control (LC),overall survival (OS) and 
toxicity. 
Results: We analyzed atotal of forty-four patients treated with 
radiochemotherapy: 17 patients received 5-fluorouracil (1000 
mg/mq/day, 96 h continuous infusion, Days 1-4)(Group 1) and 27 
patients (Group 2) Gemcitabine (300-350 mg/mq/weekly). One 
patient (of Group 2) received only radiotherapy. Twelve patients of 
Group 1 and 6 patients of Group 2 received a boost of intraluminal BT 
with 192I wires (30-50 Gy), 1 cm from the source axis. Median follow-up 
was 132 months (range 16-220) for the entire group of patients. Of 
group 1, two patients showed a complete response and others two a 
partial response; instead,of group 2, anyone showed a response. No 
difference was observed between two groups in terms of Overall 
Survival (MedianOS was 13.5 months in both gropus p=0.2). Median 
local control (LC) was 13 months for group 1 and 8.5 months for group 
2 (p=0.04). Patients receiving Gemcitabine developed an higher rate 
of acute toxicity compared to patients treated with 5FU 
(p=0.03).Patients underwent to BT had a better local control (p=0.03), 
without an increased toxicity. No impact was on Overall survival. 
Conclusions: The comparison of these two study seems to 
demonstrate a better outcome in patients treated with 5FU-
chemoradiation compared to Gemcitabine. In this study the BT seems 
to improve local control even if its role remains controversial. 
However, not all patients underwent to brachytherapy boost due to 
high toxicity from radiochemotherapy. Prospective studies in larger 
series are needed to better evaluated the possibility to anticipate the 
boost of brachytherapy before chemoradiation. 
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Purpose/Objective: External beam radiation therapy (EBRT) 
combined with intracavitary high-dose rate (HDR) brachytherapy given 
with concomitant chemotherapy is the standard treatment for locally 
advanced cervical cancer. However, intracavitary brachytherapy is not 
always feasible. Our aim in this dosimetric study was to compare 
dosimetric parameters of HDR and Cyberknife (CK) plans for boosts in 
cervical cancer patients.  
Materials and Methods: CT-based HDR plans of 14 patients with FIGO 
IB-IIIB cervical cancer treated in a single center were analysed. Each 
patient was treated with weekly cisplatinum concomitantly with EBRT 
followed with HDR boost of 30 Gy in 5 fractions. Plans were generated 
using Oncentra Brachy (Elekta) and delivered with microSelectron v2 
(Elekta). For each patient, 5 CK plans were generated by an 
experienced physicist, using MultiPlan for Cyberknife Robotic 
Radiosurgery system (Accuray). For both modalities, treatment plans 
were generated using critical organs' dose constraints recommended 
by GEC-ESTRO. Paired T tests were used to compare bladder, sigmoid, 
rectum and bowel D0.1cc, D1cc, D2cc and D5 cc. Target volume 
dosimetric parameters as well as total tissue volume parameters were 
also compared. 
Results: We are presenting preliminary results comparing 30 plans (6 
patients) in each modality. Target volume (% of volume) D100 and D90 
were significantly better for the CK plans (p=0.00). Total tissue 
volume (% of prescribed dose) V200 and V150 were significantly higher 
in HDR plans. Doses to all critical organs were higher for CK plans. 
However, they were significantly higher only for bladder D5cc 
(p=0,000) and D0.1cc (p=0.002), sigmoid D5cc (p= 0.000) and D2cc 
(p=0.015) and small bowel D5cc (p=0.000), D2cc (p=0.001) and D1cc 
(p=0.022). Low dose parameters for total tissue volume such as V50, 
V40, V30, V20 and V10 were all significantly higher in CK plans 
(p=0.000).  
Conclusions: Cyberknife plans had better target volume coverage and 
less dose heterogeneity, while HDR plans demonstrated lower doses to 
critical organs and consistently lower volume of total tissue receiving 
low doses. Based on this preliminary dosimetric study, boosting 
cervical cancer patients using CK could be an alternative in patients 
that are not eligible for intracavitary HDR brachytherapy. However, 
further clinical research is needed before this treatment modality can 
be implemented. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
